Endurance Wealth Management Inc. trimmed its position in shares of Amgen Inc. (NASDAQ:AMGN) by 0.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 31,366 shares of the medical research company’s stock after selling 56 shares during the period. Amgen accounts for approximately 1.2% of Endurance Wealth Management Inc.’s portfolio, making the stock its 26th largest holding. Endurance Wealth Management Inc.’s holdings in Amgen were worth $7,972,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Pure Financial Advisors Inc. boosted its holdings in Amgen by 2.8% in the 2nd quarter. Pure Financial Advisors Inc. now owns 1,469 shares of the medical research company’s stock worth $346,000 after buying an additional 40 shares during the period. Carroll Financial Associates Inc. grew its stake in Amgen by 0.5% in the 3rd quarter. Carroll Financial Associates Inc. now owns 7,574 shares of the medical research company’s stock worth $1,925,000 after acquiring an additional 41 shares in the last quarter. Price Wealth LLC grew its stake in Amgen by 42.9% in the 2nd quarter. Price Wealth LLC now owns 140 shares of the medical research company’s stock worth $33,000 after acquiring an additional 42 shares in the last quarter. FCG Advisors LLC grew its stake in Amgen by 3.8% in the 2nd quarter. FCG Advisors LLC now owns 1,162 shares of the medical research company’s stock worth $274,000 after acquiring an additional 42 shares in the last quarter. Finally, AFT Forsyth AND Company Inc. grew its stake in Amgen by 1.0% in the 2nd quarter. AFT Forsyth AND Company Inc. now owns 4,465 shares of the medical research company’s stock worth $1,053,000 after acquiring an additional 45 shares in the last quarter. 75.23% of the stock is owned by institutional investors and hedge funds.
In related news, Director Ronald D. Sugar sold 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $241.02, for a total transaction of $241,020.00. Also, Director R Sanders Williams sold 250 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $242.95, for a total transaction of $60,737.50. Following the sale, the director now directly owns 5,159 shares in the company, valued at $1,253,379.05. The disclosure for this sale can be found here. 0.36% of the stock is currently owned by insiders.
AMGN stock traded down $1.96 during trading on Friday, reaching $215.86. 44,166 shares of the stock were exchanged, compared to its average volume of 2,865,986. The business has a 50 day moving average price of $240.73 and a 200-day moving average price of $239.20. The firm has a market capitalization of $127.58 billion, a price-to-earnings ratio of 17.80, a P/E/G ratio of 2.01 and a beta of 0.81. Amgen Inc. has a 1 year low of $177.05 and a 1 year high of $264.97. The company has a current ratio of 2.18, a quick ratio of 1.81 and a debt-to-equity ratio of 3.20.
Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Sunday, November 1st. The medical research company reported $4.37 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.75 by $0.62. Amgen had a net margin of 30.04% and a return on equity of 91.98%. On average, research analysts anticipate that Amgen Inc. will post 15.65 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Monday, November 16th will be paid a $1.60 dividend. This represents a $6.40 dividend on an annualized basis and a dividend yield of 2.96%. The ex-dividend date is Friday, November 13th. Amgen’s dividend payout ratio (DPR) is 43.18%.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Sensipar/Mimpara to treat secondary hyperparathyroidism; and EPOGEN to treat anemia caused by chronic kidney disease.
Recommended Story: Cost of Equity For A Business, Investors
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.